US Patent
US11154498 — Stabilized liquid formulation of levothyroxine
Formulation · Assigned to Leiutis Pharmaceutials LLP · Expires 2036-07-20 · 10y remaining
Vulnerability score
42/100
Strong — defensible against typical IPR challenges
What this patent protects
This patent protects a stabilized liquid formulation of levothyroxine for parenteral administration.
USPTO Abstract
The present invention relates to stabilized liquid formulations of Levothyroxine or a pharmaceutically acceptable salt thereof, intended for parenteral administration. Further this invention also describes process of preparing such compositions.
Drugs covered by this patent
- Unithroid (LEVOTHYROXINE SODIUM) · Fresenius Kabi
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.